241 related articles for article (PubMed ID: 28991701)
1. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
[No Abstract] [Full Text] [Related]
2. Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
Beadnall HN; Gill AJ; Riminton S; Barnett MH
Neurology; 2016 Dec; 87(24):2595-2597. PubMed ID: 27856777
[No Abstract] [Full Text] [Related]
3. Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report.
Mahajan KR; Ko JS; Tetzlaff MT; Hudgens CW; Billings SD; Cohen JA
Mult Scler Relat Disord; 2017 Oct; 17():12-14. PubMed ID: 29055440
[TBL] [Abstract][Full Text] [Related]
4. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
[TBL] [Abstract][Full Text] [Related]
5. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod.
Hernández Clares R; Sánchez Pedreño P; García Vazquez E; Carreón Guarnizo E; Meca Lallana JE
Neurologia (Engl Ed); 2018 Jun; 33(5):348-349. PubMed ID: 28535923
[No Abstract] [Full Text] [Related]
6. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
[TBL] [Abstract][Full Text] [Related]
7. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
Walker S; Brew B
J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
[TBL] [Abstract][Full Text] [Related]
9. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
Christopher KL; Elner VM; Demirci H
Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
Sharim J; Tashjian R; Golzy N; Pouratian N
J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
[TBL] [Abstract][Full Text] [Related]
11. Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
Avasarala J; Jain S; Urrea-Mendoza E
J Clin Pharmacol; 2017 Nov; 57(11):1415-1418. PubMed ID: 28543950
[No Abstract] [Full Text] [Related]
12. Detection of a new melanoma in a patient treated with fingolimod.
Michiels Y; Bugnon O; Michiels JF; Mazellier S
BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 31036735
[TBL] [Abstract][Full Text] [Related]
13. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
[No Abstract] [Full Text] [Related]
14. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
[TBL] [Abstract][Full Text] [Related]
15. Early and recurrent macular oedema in a patient treated with fingolimod.
Cifuentes-Canorea P; Nieves-Moreno M; Sáenz-Francés F; Santos-Bueso E
Neurologia (Engl Ed); 2019 Apr; 34(3):206-207. PubMed ID: 27776961
[No Abstract] [Full Text] [Related]
16. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
17. Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment.
Bianco A; Patanella AK; Nociti V; De Fino C; Lucchini M; Savio FL; Rossini PM; Mirabella M
Mult Scler Relat Disord; 2016 Sep; 9():11-3. PubMed ID: 27645336
[TBL] [Abstract][Full Text] [Related]
18. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
Samaraweera AP; Cohen SN; Akay EM; Evangelou N
Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
[TBL] [Abstract][Full Text] [Related]
19. Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients.
Hovi A; Airas L
J Neuroimmune Pharmacol; 2016 Dec; 11(4):611-612. PubMed ID: 27388874
[No Abstract] [Full Text] [Related]
20. Primary cutaneous CD30
Connolly A; Grandi V; Stefanato CM; Palmer R; Weir A; Whittaker S
Br J Dermatol; 2018 Dec; 179(6):1400-1401. PubMed ID: 30007065
[No Abstract] [Full Text] [Related]
[Next] [New Search]